ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

The Pandemic Agreement Finalized, but Falls Short, says AHF

The AIDS Healthcare Foundation (AHF) and the AHF Global Public Health Institute acknowledge the conclusion of three years of negotiations on the global pandemic agreement text by congratulating the negotiators—particularly representatives of the Equity and Africa Groups—and recognizing the contributions of key stakeholders, including civil society, who championed equitable access to public health goods.

“Even before the COVID-19 pandemic, we began collaborating with non-governmental stakeholders to develop a proposal for a new global public health convention, which was published in The Lancet Public Health in May 2021,” said Dr. Jorge Saavedra, Executive Director of the AHF Global Public Health Institute. “Just a week after the discovery of the Omicron variant, the world responded with urgency, and WHO Member States established the Intergovernmental Negotiating Body (INB) to draft and negotiate a new international instrument on pandemic prevention, preparedness, and response. Several of the ideas in our Lancet article were incorporated into the discussions during the negotiations.”

Since then, AHF has been actively engaged in the negotiation process as both an advocate and coalition builder among non-governmental organizations at the country level and as an INB stakeholder. Alongside other relevant stakeholders, AHF has played a consistent role in advocating for key aspects of the agreement that are now incorporated in a final draft that promotes cooperation in research and development, geographically diversified local production, technology transfer, and establishes Pathogen Access and Benefit-Sharing System (PABS). However, AHF believes the final draft does not go far enough to ensure equitable and timely access to lifesaving medical countermeasures worldwide.

“During the COVID-19 pandemic, there was no shortage of good intentions and promises of cooperation—but as we’ve seen, words alone don’t deliver lifesaving vaccines and treatments to the people who need them most,” said AHF President Michael Weinstein. “The upcoming negotiations on financing mechanisms and the PABS annex must result in concrete, measurable, and sufficient benefits—where needs are objectively defined based on public health risk, and access to specific public health goods is guaranteed. They must also include enforceable obligations if we’re serious about making progress and avoiding a repeat of the unacceptable inequities we saw during this last pandemic.”

To the detriment of equity, the pharmaceutical industry exerted disproportionate influence over the negotiation process, pushing for the inclusion of clauses that threatened countries' sovereign rights on technology transfer. Their demands—championed by a few wealthy countries—also threatened to hold the entire agreement hostage unless included in the final text. AHF also expresses its concern about efforts by the pharmaceutical industry to use the pandemic agreement as a vehicle to encroach on the regulatory space for technology transfer and use it to undermine international norms and sovereign rights that safeguard equitable access to medicines and health technologies.

While AHF supports the anticipated adoption of the final draft agreement by the World Health Assembly, several critical steps must also be taken. These include establishing a sustainable financing mechanism; ensuring formal involvement of relevant non-state actors—including universities and civil society; strengthening regional capacity to produce, coordinate, and respond to public health emergencies; and securing a robust and enforceable PABS system.

“Article 12, which addresses PABS, falls short of ensuring equitable access to global public health goods during—and before—a pandemic is declared,” added Weinstein. “Setting a target of 20% of production is likely below what was achieved during the three years of the COVID-19 pandemic. One advantage, though, is that under this agreement, allocation of health products will occur in real time during emergencies—rather than waiting for wealthy countries to send leftovers to the rest of the world.”

“Another serious concern,” he continued, “is that the administration and coordination of the PABS system has been left to the WHO. Given their poor performance as global coordinator of COVAX during COVID-19, it’s doubtful they are equipped to manage this critical function without significant institutional reform.”

AIDS Healthcare Foundation (AHF) is a global non-profit organization providing cutting-edge medicine and advocacy to over 2.3 million people in 47 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. We are currently the largest non-profit provider of HIV/AIDS medical care in the world. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.